A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
复制标题
帕洛诺司琼对接受 CHOP 方案治疗的恶性淋巴瘤患者止吐作用的前瞻性研究。
DOI:
10.1007/s12185-016-2089-9
复制
发表时间:
2016
期刊:
影响因子:
2.1
通讯作者:
Minami H.
中科院分区:
文献类型:
--
作者:
Miyata Y;Yakushijin K;Inui Y;Imamura Y;Goto H;Mizutani Y;Kurata K;Kakiuchi S;Sanada Y;Minami Y;Kawamoto S;Yamamoto K;Ito M;Tominaga R;Gomyo H;Mizuno I;Nomura T;Kitagawa K;Sugimoto T;Murayama T;Matsuoka H;Minami H.
To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was administered at a dose of 0.75 mg via intravenous injection over 30 min before chemotherapy on day 1. Patients kept diaries of chemotherapy-induced nausea and vomiting (CINV) incidence from the start of chemotherapy until 168 h afterwards, in which they documented the occurrence and severity of nausea, vomiting, anorexia, and the use of rescue medication. The primary endpoint was the overall occurrence rate of nausea, vomiting, and anorexia; these rates were 56, 12, and 62 %, respectively, including all grades. The rates and severity of symptoms tended to worsen 120–168 h after completing oral prednisolone. We defined complete response (CR) as no vomiting and no use of rescue therapy. The CR rates of post palonosetron 0.75 mg treatment in the acute (0–24 h), delayed (24–168 h), and overall phases (0–168 h) were 86, 66, and 62 %, respectively. Antiemetic strategies of CHOP regimen for day 6 and, thereafter, should be investigated.